DRUGS & SUPPLEMENTS
How is the drug helping you?
Orudis I.M. is a NSAID, propionic acid derivative. This medication has analgesic, anti-inflammatory and antipyretic activity. The mechanism of action is associated with inhibition of COX activity - the main enzyme metabolism of arachidonic acid, a precursor of prostaglandins, which play a major role in the pathogenesis of inflammation, pain and fever. A pronounced analgesic effect of Orudis I.M. is due to two mechanisms: peripheral and central (due to inhibition of prostaglandin synthesis in the central and peripheral nervous system, as well as the influence on the biological activity of other neurotrophic substances that play a key role in the release of neurotransmitters in the spinal pain brain). In addition, this drug has anti-bradykinin activity, stabilizes lysosomal membranes, causes a significant inhibition of neutrophils in patients with rheumatoid arthritis.
After oral and rectal administration Orudis I.M. is well absorbed from the gastrointestinal tract. Cmax in plasma by ingestion is achieved through 1-5 hours (depending on dosage form), with rectal administration - after 45-60 min; IM administration - after 20-30 min; IV injections - after 5 minutes.
The plasma protein binding is 99%. Due to the lipophilicity expressed rapidly penetrates the BBB. Css in plasma and cerebrospinal fluid stored between 2 and 18 h.
Orudis I.M. well penetrates into synovial fluid, where its concentration is 4 hours after admission exceeds that in plasma.
This medicine is metabolized by binding to glucuronic acid and to a lesser extent by hydroxylation.
Orudis I.M. is excreted primarily by kidneys and to a lesser extent through the intestines. T1/2 of Orudis I.M. from plasma after oral administration is 1.5-2 h; after rectal administration - about 2 hours; IM administration - 1.27 hours, IV injections - 2 hours.
Articular syndrome ; symptomatic treatment of inflammatory and degenerative diseases of the musculoskeletal (shoulder, artrosinovit, tendonitis, tenosynovitis, bursitis, lumbago), back pain, neuralgia, myalgia. Uncomplicated trauma, particularly sports, sprains, sprain or rupture of ligaments and tendons, bruises, post-traumatic pain. As part of combination therapy of inflammatory diseases of veins, lymphatic vessels, lymph nodes (phlebitis, periflebit, lymphangitis, lymphadenitis surface).
The dosage regimen set individually according to the severity of the disease. For oral administration in adult the initial daily dose is 300 mg in 2-3 doses. For maintenance treatment the dose depends on the dosage form. For the treatment of acute conditions or exacerbations of chronic edema of the process this medication is administered in 100 mg as a single IM injection. Next Orudis I.M. administered orally or rectally.
Topically this drug used to the skin surface 2 times / day.
The maximum dose oral or rectal administration is 300 mg / day.
Digestive system: epigastric pain, nausea, vomiting, constipation or diarrhea, anorexia, gastralgia, liver, rarely - erosive and ulcerative lesions of the gastrointestinal tract, gastrointestinal bleeding and perforation.
CNS: headache, dizziness, tinnitus and drowsiness.
Urinary system: kidney damage.
Allergic reactions: skin rash, rarely - bronchospasm.
Local reactions: when Orudis I.M. used in rectal suppositories it is possible irritation of the mucous membrane of the rectum, painful defecation, when this medication used in a gel form - itching, skin rash at the site of application.
For oral administration: erosive and ulcerative lesions of the gastrointestinal tract in acute phase, "aspirin triad" expressed by the human liver and / or kidney disease; III trimester of pregnancy; age up of 15 years ; increased sensitivity to Orudis I.M. and salicylates.
For rectal administration: proctitis and bleeding from the rectum in history.
For external use: moist dermatitis, eczema, infected abrasions and wounds.
Orudis I.M. is contraindicated for use in the III trimester of pregnancy. In I and II trimesters of pregnancy the use of Orudis I.M. may be in cases when the potential benefit to the mother outweighs the potential risk to the fetus.
If necessary to use Orudis I.M. in lactating a breast-feeding should be stopped
.Category of the fetus by FDA - C.
With great caution use Orudis I.M. in patients with liver and kidney, gastrointestinal tract diseases in the history of dyspeptic symptoms after major surgery. In the course of treatment it requires systematic monitoring of liver and kidney.
When this drug applied simultaneously with:
- other NSAIDs increases the risk of erosive and ulcerative lesions of the gastrointestinal tract and bleeding
- antihypertensive drugs it may decreases their actions
- aspirin may decrease the binding of Orudis I.M. to plasma proteins and increase its plasma clearance
- heparin, ticlopidine increase risk of bleeding
- lithium therapy - it may increase the concentration of lithium in blood plasma to the toxic by reducing its renal excretion
- diuretics increases the risk of renal failure due to a decrease in renal blood flow caused by inhibition of prostaglandin synthesis, and against the background of hypovolemia
- probenecid it may decreases the clearance of Orudis I.M. and its binding to plasma proteins
- methotrexate - may increase the side effects of methotrexate
- warfarin may develop severe, sometimes fatal bleeding.
Symptoms: lethargy, dizziness, nausea, vomiting, epigastric pain - these symptoms are usually reversible. May be respiratory distress, coma, convulsions. Rarely - bleeding from the gastrointestinal tract, hypotension / hypertension, acute renal failure.
Treatment: symptomatic and supportive therapy, monitoring of respiratory and cardiovascular systems. The is no a specific antidote. Hemodialysis is ineffective.
Depending on the reaction of the Orudis I.M. after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Orudis I.M. not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.Is Orudis I.M. addictive or habit forming?
Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.
Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.
There are no reviews yet. Be the first to write one!
The information was verified by Dr. Rachana Salvi, MD Pharmacology